Page 21 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine Advancements and challenges in radioactive iodine-125

71. Ishihara D, Pop L, Takeshima T, et al., 2017, Rationale and relationship with lung cancer. PLoS One, 12: e0173048.
evidence to combine radiation therapy and immunotherapy https://doi.org/10.1371/journal.pone.0173048
for cancer treatment. Cancer Immunol Immunother, 66:
281–298. 77. Wang X, Liu Y, Dai L, et al., 2016, Foxp3 downregulation
in NSCLC mediates epithelial-mesenchymal transition via
https://doi.org/10.1007/s00262-016-1914-6 NF-kappaB signaling. Oncol Rep, 36: 2282–2288.
72. Cabel L, Loir E, Gravis G, et al., Long-term complete https://doi.org/10.3892/or.2016.5024
remission with Ipilimumab in metastatic castrate-resistant
prostate cancer: Case report of two patients. J Immunother 78. Wada S, Harris TJ, Tryggestad E, et al., Combined treatment
Cancer, 5: 31. effects of radiation and immunotherapy: Studies in an
autochthonous prostate cancer model. Int J Radiat Oncol
https://doi.org/10.1186/s40425-017-0232-7 Biol Phys, 87: 769–776.
73. Tumeh PC, Harview CL, Yearley JH, et al., 2014, PD-1 https://doi.org/10.1016/j.ijrobp.2013.07.015
blockade induces responses by inhibiting adaptive immune
resistance. Nature, 515: 568–571. 79. Nardone V, Botta C, Caraglia M, et al., 2016, Tumor
infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1
https://doi.org/10.1038/nature13954 predict the outcome of prostate cancer patients subjected to
74. Arina A, Karrison T, Galka E, et al., 2017, Transfer of salvage radiotherapy after biochemical relapse. Cancer Biol
allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD- Ther, 17: 1213–1220.
L1-resistant tumors leading to tumor eradication. Cancer https://doi.org/10.1080/15384047.2016.1235666
Immunol Res, 5: 127–136.
80. Harris TJ, Hipkiss EL, Borzillary S, et al., 2008, Radiotherapy
https://doi.org/10.1158/2326-6066.CIR-16-0293 augments the immune response to prostate cancer in a time-
75. Sallin MA, Sakai S, Kauffman KD, et al., 2017, Th1 dependent manner. Prostate, 68: 1319–1329.
differentiation drives the accumulation of intravascular, https://doi.org/10.1002/pros.20794
non-protective CD4 T cells during tuberculosis. Cell Rep, 81. Mittal D, Gubin MM, Schreiber RD, et al., 2014, New insights
18: 3091–3104.
into cancer immunoediting and its three component phases-
https://doi.org/10.1016/j.celrep.2017.03.007 -elimination, equilibrium and escape. Curr Opin Immunol,
27: 16–25.
76. Hou PF, Zhu LJ, Chen XY, et al., Age-related changes
in CD4+CD25+FOXP3+ regulatory T cells and their https://doi.org/10.1016/j.coi.2014.01.004

Volume 1 Issue 2 (2023) 13 https://doi.org/10.36922/arnm.0914